RECRUITING

ACDF Using Structural Allograft Vs. Tritanium C

Conditions

Degenerative Disc Disease Tritanium C Structural Bone Graft Anterior Cervical Discectomy and Fusion

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational, descriptive, prospective and retrospective data collection study. The purpose of this study is to observe radiographic outcomes of patients who will undergo anterior cervical discectomy and fusion (ACDF) utilizing Tritanium C (Stryker Spine). The rate of fusion success and adverse events will be compared retrospectively to patients who underwent instrumented ACDF utilizing structural allograft bone with plates.

Official Title

Comparison of Clinical Outcomes Following ACDF with Instrumentation Using Structural Allograft Vs. Tritanium C

Quick Facts

Study Start:2020-08-20

Study Completion:2026-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04388332

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Males or females ≥18 years of age, ≤ 80 years of age 2. Subject is skeletally mature 3. Subject is diagnosed with degenerative disc disease (DDD) at one level or two contiguous levels from the C2 -T1 disc 4. Subject has received six weeks of non-operative therapy i.e. injections, physical therapy, oral steroids 5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent (Prospective study) 6. Subjects that will prospectively undergo one or two level anterior cervical discectomy and fusion with Tritanium C (Prospective study) 7. Subjects that underwent one or two level anterior cervical discectomy and fusion with either standard of care structural allograft bone at any AHN facility from 01/01/2016 to 08/14/2023 (Retrospective study) • Note that these patients will be followed for a maximum of one year (up to 08/14/2024 for a patient enrolled at the end of this inclusion period)	1. Presence of an infection systemic or local 2. Presence of marked local inflammation 3. Subject has any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis 4. Use of bone growth stimulator 5. Subject has prior fusion at the levels to be treated 6. Subject has any neuromuscular deficit 7. Subject has any condition of senility, mental illness, or substance abuse 8. Subject has any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery in the judgement of the PI 9. Subject has rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis. Subject is pregnant or plans to become pregnant during the course of the study. 10. BMI≥40 kg/m2 11. Subject uses chronic corticosteroids 12. Subjects with current active psychiatric diagnosis or a personality disorder likely to interfere with the study 13. Subjects who smoke and do not plan to quit 14. Mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care 15. Subject has any open wounds 16. Subject has inadequate tissue coverage over the operative site 17. Subject may be sensitive to titanium materials 18. Subject is missing 6 and/or 12 month clinical or radiographic follow-up (Retrospective study)

Inclusion Criteria

Exclusion Criteria

1. Males or females ≥18 years of age, ≤ 80 years of age
2. Subject is skeletally mature
3. Subject is diagnosed with degenerative disc disease (DDD) at one level or two contiguous levels from the C2 -T1 disc
4. Subject has received six weeks of non-operative therapy i.e. injections, physical therapy, oral steroids
5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent (Prospective study)
6. Subjects that will prospectively undergo one or two level anterior cervical discectomy and fusion with Tritanium C (Prospective study)
7. Subjects that underwent one or two level anterior cervical discectomy and fusion with either standard of care structural allograft bone at any AHN facility from 01/01/2016 to 08/14/2023 (Retrospective study) • Note that these patients will be followed for a maximum of one year (up to 08/14/2024 for a patient enrolled at the end of this inclusion period)

1. Presence of an infection systemic or local
2. Presence of marked local inflammation
3. Subject has any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis
4. Use of bone growth stimulator
5. Subject has prior fusion at the levels to be treated
6. Subject has any neuromuscular deficit
7. Subject has any condition of senility, mental illness, or substance abuse
8. Subject has any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery in the judgement of the PI
9. Subject has rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis. Subject is pregnant or plans to become pregnant during the course of the study.
10. BMI≥40 kg/m2
11. Subject uses chronic corticosteroids
12. Subjects with current active psychiatric diagnosis or a personality disorder likely to interfere with the study
13. Subjects who smoke and do not plan to quit
14. Mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care
15. Subject has any open wounds
16. Subject has inadequate tissue coverage over the operative site
17. Subject may be sensitive to titanium materials
18. Subject is missing 6 and/or 12 month clinical or radiographic follow-up (Retrospective study)

Contacts and Locations

Study Contact

Nestor Tomycz, MD

CONTACT

412-359-6200

nestor.tomycz@ahn.org

Alexander Yu, MD

CONTACT

412-359-6200

alexander.yu@ahn.org

Principal Investigator

Nestor Tomycz, MD

PRINCIPAL_INVESTIGATOR

Allegheny Health Network

Study Locations (Sites)

Allegheny Health Network

Pittsburgh, Pennsylvania, 15212

United States

Collaborators and Investigators

Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Nestor Tomycz, MD, PRINCIPAL_INVESTIGATOR, Allegheny Health Network

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-08-20

Study Completion Date2026-12

Study Record Updates

Study Start Date2020-08-20

Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

Tritanium C
Structural Bone Graft
Anterior Cervical Discectomy and Fusion

Additional Relevant MeSH Terms

Degenerative Disc Disease